Status:
NO_LONGER_AVAILABLE
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
Lead Sponsor:
Pfizer
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma
Detailed Description
In Expanded Access, treating physicians are the Sponsors Expanded Access requests from treating physicians should be directed to www.pfizercares.com Availability will depend on location.
Eligibility Criteria
Inclusion
- Must have relapsed/refractory multiple myeloma (RRMM) and be refractory to at least one immunomodulatory drug, one proteasome inhibitor and one anti-CD38 antibody. Must have evidence of disease progression after last therapy. Must have exhausted all available treatment options accessible as local standard of care and not be eligible for participation in any ongoing clinical trial. Additional eligibility criteria may be required.
Exclusion
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05238311
Last Update
February 4 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.